215610-30-3

Usage

General Description

1H-Pyrazole, 3-methoxy- is a chemical compound with the molecular formula C4H6N2O. It is a derivative of pyrazole, a five-membered ring with two nitrogen atoms at opposite positions. The presence of a methoxy group (-OCH3) on the third position of the pyrazole ring distinguishes 1H-Pyrazole, 3-methoxy-. 1H-Pyrazole, 3-methoxy- is used in various research and industrial applications, including pharmaceuticals, agrochemicals, and materials science. Its chemical structure and properties make it suitable for use as a building block in the synthesis of more complex organic molecules. Additionally, it has potential biological and pharmacological activities, which make it a subject of interest for researchers in the fields of medicinal chemistry and drug development.

Upstream product

• 852471-15-9 1-acetyl-1,2-dihydro-3H-pyrazol-3-one 
• 77-78-1 dimethyl sulfate 
• 34846-90-7 methyl 3-methoxyprop-2-enoate 
• 1361329-17-0 methyl 3-methoxy-1H-pyrazole-4-carboxylate 
• 1146950-69-7 tert-butyl 4-(4-bromo-3-methoxy-pyrazol-1-yl)piperidine-1-carboxylate 
• 186581-53-3 diazomethane 
• 137-45-1 1,2-dihydropyrazol-3-one 

Downstream Products

• 1350325-05-1 3-methoxy-4-iodopyrazole 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships

Acid ceramidase (AC) is a lysosomal cysteine amidase responsible for the cleavage of ceramide into sphingosine, which is then phosphorylated to sphingosine 1-phosphate. AC regulates the intracellular levels of ceramide and sphingosine, and AC inhibition may be useful in the treatment of disorders, such as cancer, in which ceramide-mediated signaling may be dysfunctional. Despite their potential experimental and therapeutic value, the number of available small-molecule inhibitors of AC activity remains limited. In the present study is described the discovery of a class of potent pyrazole carboxamide-based AC inhibitors, which were identified using the atomic property field (APF) approach and developed through systematic SAR investigations and in vitro pharmacological characterization. The best compound of this series inhibits AC with nanomolar potency and causes ceramide accumulation and sphingosine depletion in intact G361 proliferative melanoma cells. By expanding the current armamentarium of AC inhibitors, these results should facilitate future efforts to unravel the biology of AC and the therapeutic potential of its inhibition.

MACROCYCLIC KINASE INHIBITORS

Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.

Few unexpected results from a Suzuki-Miyaura reaction

In the course of the synthesis of original anti-infectious compounds we focused on the palladium-catalyzed Suzuki-Miyaura aryl-aryl coupling reaction between 2-(3-ethoxy-5-iodo-1H-pyrazol-1-yl)pyridine and phenylboronic acid. A study of the reaction products obtained under different conditions (various ligands and solvents), not only provided us with insights to optimize this reaction but also with few side compounds, resulting from CH activation, along with the unexpected bis(3-ethoxy-1-(pyridin-2-yl)-1H-pyrazol-5-yl)palladium. Stochiometric experiments with this remarkably stable biscyclopalladated reagent and phenylhalides pointed out the occurrence of aryl-aryl coupling, possibly via palladium IV intermediates.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

Alkoxypyrazoles and the process for their preparation

The present invention relates to a process for the preparation of alkoxypyrazoles and new alkoxypyrazole compounds.

PYRIDINE AND PYRAZINE DERIVATIVES - 083

The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

1,2,3-Triazines, V1: Lithiation of 1,2,3-triazines

5-Ethoxy-1,2,3-triazine (15) can be mono- and dilithiated and the lithio-1,2,3-triazines (16, 17) were reacted with aldehydes to give 18a-c, 19a-c, 20a-c and 21a-c. 18-21 can be oxidized to give the benzoyl-1,2,3- triazines 22a-c, 23c and 24a-c. Condensation of 24c with hydrazine afforded the pyrazolo[4.3-d]1,2,3-triazine 25 and 24a-c with ethylene diamine afforded the 1,2,3-triazino[5,4-e][1,4]diazepines 27a-c. 4-Methoxy-1,2,3-triazine (12) forms as well the 5- as the 6-lithio-4-methoxy-1,2,3-triazine (28a,b), whose reaction with benzaldehyde gave the 5- and 6-(α-hydroxybenzyl)-4,methoxy- 1,2,3-triazines (29a,b), respectively.